staging In all cases, adequate staging should be carried out to exclude the presence of extracutaneous disease. Staging includes complete physical examination, complete and differential blood cell count and serum biochemistry and appropriate imaging studies (computed tomography scans ± [ 18 F]2-fluoro-2-deoxy-D-glucose-positron emission tomography scans in all but stage IA), although they are not required in patients with lymphomatoid papulosis (LyP) [5, 6] . Flow cytometry of the peripheral blood should only be carried out in selected cases, but is mandatory in patients with (suspected) Sézary syndrome (SS). Bone marrow biopsy and aspiration should be carried out in cutaneous lymphomas with an intermediate or aggressive clinical behaviour, but is not required in cutaneous lymphomas with an indolent clinical behaviour (MF, cutaneous anaplastic large-cell lymphoma and cutaneous marginal zone lymphoma), unless indicated by other staging assessments [5, 6] . The significance of bone marrow examination in primary cutaneous follicle centre lymphoma (PCFCL) is controversial [6, 7] . Prognosis is extremely variable depending on the type of PCL and the stage of disease. For clinical staging of MF and SS, the revised International Society for Cutaneous Lymphomas/European Organization of Research and Treatment of Cancer (ISCL/EORTC) TNMB (tumour-node-metastasis-blood) staging system should be used (Tables 2 and 3 ) [5] . For PCL other than MF/SS, a separate ISCL/EORTC TNM classification system has been published [6] . This staging system is primarily intended to document the extent of disease and cannot be used as a prognostic guide. 
mycosis fungoides and variants
Since early aggressive chemotherapy is associated with considerable side-effects but does not improve survival, a stageadapted conservative therapeutic approach is recommended for MF and its variants [9] [10] [11] [12] . Patients with only patches and/or plaques covering <10% (stage IA) or ≥10% of the skin surface (stage IB) should be treated with skin-directed therapies, including topical steroids, psoralens + ultraviolet A (PUVA), narrow-band ultraviolet B (UVB) and topical cytostatic agents, such as mechlorethamine or carmustine (BCNU). Narrow-band UVB should only be used in patients with patches or very thin plaques. Topical steroids can be recommended as monotherapy for patches/flat plaques stage IA disease. In stage IB, topical steroids can be used as adjuvant therapy for selected skin lesions. In patients developing one or few infiltrated plaques or tumours (stage IIB), additional local radiotherapy may suffice. Local radiotherapy can be curative in patients with early localised disease, particularly in patients with unilesional MF and pagetoid reticulosis. Local radiotherapy is most commonly administered with electrons (energy dependent on the thickness of the lesion), with bolus to achieve full skin dose, a margin of ≥2 cm and a total dose of 24-36 Gy. For patients with more extensive infiltrated plaques and tumours or patients refractory to skin-directed therapies, a combination of PUVA and interferon alpha or PUVA and retinoids (including bexarotene), a combination of interferon alpha and retinoids or total skin electron beam irradiation can be considered. However, these treatments are not curative, although remission may last for several years. Total skin electron beam irradiation was often given to total doses of 30-36 Gy, but recently lower doses (10-12 Gy) have been employed with the advantages of shorter duration of the treatment period, fewer side-effects and opportunity for re-treatment [13] . In patients with advanced and refractory disease, gemcitabine or liposomal doxorubicin may be considered [14, 15] . Other agents like the fusion toxin denileukin diftitox and histone deacetylase (HDAC) inhibitors, such as vorinostat and romidepsin, have been approved in the United States by the Food and Drug Administration (FDA) for patients with relapsed and refractory CTCL, but have not yet been registered for CTCL in Europe [16] [17] [18] . Multiagent chemotherapy is only indicated in patients with effaced lymph nodes or visceral involvement (stage IV), or in patients with widespread tumour stage MF which cannot be controlled with skin-targeted and immunomodulating therapies. Local palliation of cutaneous as well as extracutaneous lesions may be achieved with local radiotherapy to doses ≥8 Gy [19] . In relatively young patients with refractory, progressive MF or with SS, allogeneic stem cell transplantation may be considered. Durable responses have been reported, but experience is still limited, and the optimal conditioning regimen and the optimal timing for an allogeneic transplant are currently unknown [20] . Results with autologous stem cell transplantation in MF and SS have been disappointing.
Sézary syndrome
Being a systemic disease (i.e. leukaemia) by definition, systemic treatment is required. Skin-directed therapies like PUVA or potent topical steroids may be used as adjuvant therapy. Extracorporeal photopheresis (ECP), either alone or in combination with other treatment modalities such as interferon alpha, retinoids, total skin electron beam and PUVA, has been suggested as the treatment of choice in SS and erythrodermic MF [10] [11] [12] . Overall response rates range from 30% to 80% with complete response rates ranging from 14% to 25%, depending on the ECP regimen and the type of combination used. However, the suggested superiority of ECP over the traditional low-dose chemotherapy regimens has not yet been substantiated by randomised, controlled trials [21] . Prolonged treatment with a combination of low-dose chlorambucil and prednisone is often effective in controlling the disease, but is unlikely to yield complete responses. Low-dose methotrexate, bexarotene, denileukin diftitox, alemtuzumab (low-dose) and multiagent chemotherapy have been recommended as second-line treatment of SS [10] [11] [12] 22] . It should be emphasised that comparison of treatment results in the different studies is almost impossible due to differences in diagnostic criteria used for SS.
primary cutaneous CD30-positive lymphoproliferative disorders (LPDs)
The group of primary cutaneous CD30-positive LPDs includes primary cutaneous anaplastic large lymphoma (C-ALCL) and LyP, which form a spectrum of disease. Both C-ALCL and LyP have an excellent prognosis, with a 10-year survival of 90% and almost 100%, respectively [23, 24] . Patients with C-ALCL generally present with solitary or localised (ulcerating) tumours or nodules and should be treated with radiotherapy or surgical excision. Patients with C-ALCL presenting with multifocal skin lesions can be best treated with low-dose methotrexate, as in LyP, or radiotherapy in case of only a few lesions. Radiotherapy is commonly administered with electrons, with bolus, a margin of ≥2 cm and a total dose of 40 Gy [25] . This dose is effective and well-tolerated. Lower doses may achieve the same result, but data have not been published. In patients with multiple lesions, lower doses of radiation may be used for palliation. In cases not responsive to these treatments, systemic retinoids including bexarotene or interferon alpha can be used [24] . Recent preliminary studies report high response rates of brentuximab vedotin (anti-CD30 monoclonal antibody coupled to the antitubulin agent monomethyl auristatin E) in patients with C-ALCL as well as patients with MF expressing CD30, but controlled clinical trials have just started [26, 27] . Multiagent chemotherapy is only indicated in patients presenting with or developing extracutaneous disease and in rare patients with rapidly progressive skin disease.
subcutaneous panniculitis-like T-cell lymphoma (SPTCL)
The term SPTCL is only used for cases with an α/β T-cell phenotype, which have a favourable prognosis, particularly if not associated with a haemophagocytic syndrome (HPS), which is frequently an extremely aggressive clinical syndrome requiring immediate intervention. One study reported 5-year overall survival rates of 91% and 46% in SPTCL patients without and with an HPS, respectively [28] . In SPTCL without associated HPS, systemic steroids or other immunosuppressive agents should be considered first, whereas in cases of solitary or localised skin lesions, radiotherapy with electrons is advised. Little information on radiation dose is available, but a dose of 40 Gy has been used. Bexarotene may be also effective in SPTCL [29] . Multiagent chemotherapy is required only in cases with progressive disease not responding to immunosuppressive therapy or in cases with HPS.
extranodal natural killer (NK)/T-cell lymphoma, nasal type
Extranodal NK/T-cell lymphoma, nasal type is a rare, nearly always Epstein-Barr virus-positive lymphoma, which is more common in Asia and Central and South America. The skin is the second most common site of involvement after the nasal cavity/nasopharynx. Patients generally present with multiple (ulcerating) plaques and tumours, or in the case of nasal NK/T-cell lymphoma with a midfacial destructive tumour. Skin involvement may be a primary or secondary manifestation of the disease. One study reported a median survival of 27 months for patients presenting with only skin lesions, compared with 5 months for patients presenting with cutaneous and extracutaneous diseases [30] . Since both groups have an aggressive clinical behaviour, distinction between primary and secondary cutaneous involvement seems not to be useful for this category. In patients with stage I disease, radiotherapy is the first choice of treatment. Recommended radiation doses are higher than for other lymphomas, with 50 Gy to the initial lesion and a boost of 5-10 Gy to residual disease. In the case of more advanced disease, these lymphomas show an aggressive clinical behaviour and are often resistant to chemotherapy.
Recently, an intensive chemotherapy regimen including L-asparaginase (the SMILE regimen) was shown to be effective [31] .
primary cutaneous peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS)
Within the group of primary cutaneous PTCL-NOS, three somewhat better defined subgroups have been included as provisional entities (see Table 1 ). However, most of the cases have in common a generally aggressive clinical course and poor survival, and should therefore be treated as systemic PTCL-NOS with multiagent chemotherapy. Since the results are often disappointing, early allogeneic stem cell transplantation may be considered. The only exception is the group of CD4-positive small-medium pleomorphic CTCL. These patients often present with a solitary tumour, most commonly on the head, should be treated with local radiotherapy or excision, and have an excellent prognosis.
cutaneous B-cell lymphoma
In the WHO-EORTC classification, three main types of CBCL are distinguished: primary cutaneous marginal zone lymphoma [32] . Recommended radiation doses for localised PCMZL and PCFCL are 24-36 Gy, whereas for palliative treatment of multifocal disease, low-dose radiation (4 Gy) is often sufficient [19] . For the more aggressive PCLBCL-LT, a radiation dose of 40 Gy is recommended.
personalised medicine
In this disease setting, more research is needed to identify molecular markers which could lead to advances in personalised medicine.
follow-up
The frequency of follow-up visits depends on the type of PCL and the stage of disease. It may vary from every 6 or 12 months in patients with indolent types of PCL and stable disease or patients in complete remission to every 4-6 weeks in patients with active or progressive disease. Follow-up visits should focus on history and physical examination, and additional testing (histology, blood examination, imaging, etc.) should only be carried out if required.
note
According to the levels of evidence and grades of recommendation shown in Table 5 , the levels of evidence in these guidelines are mostly level IV and the recommendations are grade B. This is due to the heterogeneity and rarity of the diseases.
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